Jialei Wang

8PUBLICATIONS
34CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 11, 2026
Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1.

|Sep 11, 2026
Bevacizumab plus nab-paclitaxel and platinum as second-line therapy for driver-gene-negative non-squamous non-small cell lung cancer after immunochemotherapy: A prospective single-arm single-centre study.

|Mar 09, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim

|Jan 20, 2025
EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China.

Wenyue Yang, Xiangran Feng, Jian Ni

|Mar 27, 2024
Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real-world analysis.

Yao Zhang, Huiting Li, Bo Yu

|Apr 04, 2023
Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.

Jiatao Liao, Hongyan Lai, Chang Liu

Pageof 2

Frequent Collaborators

3 joint publications

Zhihuang Hu

2 joint publications

Ying Lin

2 joint publications

Wenyue Yang

2 joint publications

Xin Zhang